이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Near-infrared Transcranial Laser Therapy in Subjects With Major Depressive Disorder (ELATED-4)

2026년 9월 20일 업데이트: NeuroThera DE

Near-infrared Transcranial Laser Therapy in Subjects With Major Depressive Disorder: A Study of Dosing With Laser.

Major depressive disorder (MDD) is a leading cause of disability worldwide, and many patients do not achieve adequate benefit from current treatments. Transcranial photobiomodulation (tPBM) is a non-invasive neuromodulation technique that delivers near-infrared (808 nm) light through the scalp to frontal brain regions involved in mood regulation. Preclinical and early clinical studies suggest that tPBM may improve symptoms of depression and enhance cortical function.

This randomized, sham-controlled, parallel-group trial evaluates the efficacy, safety, and neural effects of tPBM in adults with MDD. Participants are assigned to one of four groups: Continuous Wave, Medium Dose (CW), Continuous Wave, Low Dose (CW_LOW), Pulsed Wave (PW), or Sham treatment. Interventions are delivered 3 times a week for 6 weeks (total of 18 sessions) to bilateral frontal scalp sites (AF3/F3 and AF4/F4).

The primary outcome is change in depressive symptoms measured by the Hamilton Depression Rating Scale (HAMD-17) from baseline to the end of treatment (Week 6, Visit 18).

Secondary outcomes include changes in self-reported depression scales (QIDS, SDQ), regional brain glucose metabolism measured by FDG-PET, and resting-state EEG markers. Safety and tolerability are assessed throughout the trial, including adverse events, scalp/site reactions, and suicidality screening.

This study will provide proof-of-concept evidence for the clinical efficacy and mechanistic effects of tPBM in major depression and will inform the design of larger, multicenter clinical trials.

연구 개요

상세 설명

This randomized, sham-controlled, parallel-group clinical trial evaluates the efficacy and safety of transcranial photobiomodulation (tPBM) for adults with major depressive disorder (MDD). Participants are randomly assigned in equal proportions to one of four intervention arms:

  1. CW (Continuous Wave, Medium Dose): 808 nm near-infrared laser delivered continuously at an irradiance of 300 mW/cm².
  2. CW_LOW (Continuous Wave, Low Dose): 808 nm near-infrared laser delivered continuously at an irradiance of 50 mW/cm².
  3. PW (Pulsed Wave): 808 nm near-infrared laser delivered at an average irradiance of 300 mW/cm². Pulse parameters include a frequency of 42 Hz and a duty cycle of 33%, resulting in a peak irradiance of 900 mW/cm².
  4. SHAM: Identical device without therapeutic light emission. Irradiance = 0 mW/cm².

Treatments are administered three times per week for six consecutive weeks, for a total of 18 treatment sessions. Each treatment session consists of bilateral application to frontal scalp regions corresponding to AF3/F3 and AF4/F4 exposure sites. Each exposure area measures 12 cm², with both sites irradiated simultaneously for 429 seconds per session.

PET Substudy: A subset of 20 participants underwent 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging at baseline (V0) and post-treatment (V18). Following intravenous tracer injection, participants rested quietly for approximately 30 minutes before scanning. Each 30-minute imaging session comprised three consecutive 10-minute acquisition blocks: Block A (no light), Block B (during which 429 seconds of tPBM or sham was delivered according to randomized assignment), and Block C (no light). Blocks A and C were light-free in every arm. The primary PET region of interest was the frontal lobe; the secondary region of interest was the dorsolateral prefrontal cortex (DLPFC); additional cortical and limbic regions were examined in exploratory analyses.

EEG Assessments: Resting-state electroencephalography (EEG) was recorded at V1, V9, and V18 to evaluate spectral power (delta, theta, alpha, beta bands) and connectivity indices.

Safety Assessments: Safety and tolerability are evaluated at every visit, including collection of adverse events (AEs), serious adverse events (SAEs), scalp/site tolerability ratings (e.g., erythema, discomfort), suicidality screening with the Columbia Suicide Severity Rating Scale (C-SSRS), and reasons for discontinuation.

Hypotheses: The primary hypothesis is that CW tPBM will result in a significantly greater reduction in depressive symptom severity (HAMD-17 total score) compared with SHAM at week 6/Visit 18. Secondary hypotheses include improvement in QIDS and SDQ scores, increased FDG-PET metabolism in the frontal lobe, and normalization of EEG markers.

연구 유형

중재적

등록 (실제)

50

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Lima Province
      • Lima, Lima Province, 페루, 15036
        • Clinica Vesalio
      • Lima, Lima Province, 페루, L01
        • Hospital Nacional Guillermo Almenara Irigoyen

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

The age of subjects in the study will be between 18 and 75 years (inclusive). Diagnosis of Major Depressive Disorder (MINI). QIDS-C ≥12 at screening. CGI-S ≥4 or higher, i.e., "moderately depressed." Women of childbearing potential must use a double-barrier method of birth control (e.g., condoms plus spermicides) if sexually active.

Written informed consent was obtained from the subject in accordance with local regulations prior to enrollment in this study.

The subject is willing to participate in this study for at least 12 weeks. Subjects must have been on stable doses of antidepressants (if taking any) for at least six weeks before enrollment.

Exclusion Criteria:

A decrease in self-reported SDQ from screening to baseline ≥30%, calculated as [((SDQ_screening-88) - (SDQ_baseline-88)) / (SDQ_screening-88)] ≥30/100. A score of 88 is considered "normal" on the SDQ.

The subject is pregnant or breastfeeding. The subject has failed more than 2 adequate treatments with FDA-approved antidepressants during the current episode according to ATRQ criteria (less than a 50% reduction in depressive symptoms).

Structured psychotherapy focused on treating depression (i.e., CBT or IPT) is allowed if initiated at least 8 weeks before the screening visit.

Substance dependence or abuse in the past 3 months. History of a psychotic disorder or psychotic episode (current psychotic episode as per MINI evaluation).

Bipolar affective disorder (as determined by MINI evaluation). Unstable medical illness, is defined as any medical condition that is not well controlled with standard care medications (e.g., insulin for diabetes mellitus, HCTZ for hypertension).

Active suicidal or homicidal ideation (both intent and plan are present), as determined by C-SSRS screening.

The subject has a significant skin condition (e.g., hemangioma, scleroderma, psoriasis, rash, open wound, or tattoo) on the scalp near any of the procedure sites.

The subject has any type of implant in the head (e.g., stent, clipped aneurysm, embolized AVM, implantable shunt - Hakim valve).

Any use of light-activated medications (photodynamic therapy) within 14 days prior to study enrollment (in the U.S.: Visudyne (verteporfin) - for age-related macular degeneration; Aminolevulinic Acid - for actinic keratosis; Photofrin (porfimer sodium) - for esophageal cancer, non-small cell lung cancer; Levulan Kerastick (aminolevulinic acid HCl) - for actinic keratosis; 5-aminolevulinic acid (ALA) - for non-melanoma skin cancer).

Recent history of stroke (within 90 days). The subject had a failed intervention with an FDA-approved device for depression treatment during the current episode (e.g., less than a 50% reduction in depressive symptoms with TMS, ECT, or VNS).

History of dementia, traumatic brain injury (TBI), or any other organic neurological disorder.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm A - Experimental: Continuous Wave (CW, Medium Dose)

Participants receive bilateral tPBM with 808-nm near-infrared light delivered in continuous-wave mode simultaneously to two scalp sites, centered over EEG positions AF3/F3 and AF4/F4. A diffractive optical element produces a near-uniform, round beam of approximately 12 cm² at each site (approximately 24 cm² total irradiated area). Average irradiance is approximately 300 mW/cm², corresponding to approximately 3.6 W of optical power per site and approximately 7.2 W for both sites combined. Each session lasts 429 seconds, delivering approximately 129 J/cm² per site, approximately 1.54 kJ per site, and approximately 3.09 kJ per session for both sites combined. Treatments are administered 3 times weekly for 6 weeks (18 sessions total), for a cumulative exposure of approximately 2.32 kJ/cm² per site, approximately 27.8 kJ per site, and approximately 55.6 kJ for both sites combined over the entire treatment course.

808-nm near-infrared laser light is delivered through a headset forming approximately uniform, round beams of approximately 12 cm² at each of 2 bilateral frontal scalp sites (EEG positions AF3/F3 and AF4/F4; approximately 24 cm² total), irradiated simultaneously. Arms: (1) CW, Medium Dose, approximately 300 mW/cm² average irradiance (3.6 W per site; 7.2 W both sites); (2) CW_LOW, approximately 50 mW/cm² (0.6 W per site; 1.2 W both sites); (3) PW, 42 Hz, 33% duty cycle, peak approximately 900 mW/cm² (10.8 W per site; 21.6 W both sites), average approximately 300 mW/cm² (3.6 W per site; 7.2 W both sites); (4) Sham, identical device and procedural cues, no therapeutic emission (0 mW/cm²). Sessions lasted 429 seconds, 3 times weekly for 6 weeks (18 sessions). Sham duration and procedures matched the active arms to maintain blinding.

다른 이름들:
  • 근적외선-TLT
실험적: Arm B - Experimental: Continuous Wave Low Dose (CW_LOW)

Participants receive bilateral 808-nm continuous-wave tPBM over AF3/F3 and AF4/F4 through two round beams of approximately 12 cm² each (approximately 24 cm² total). Average irradiance is approximately 50 mW/cm², corresponding to approximately 0.6 W per site and approximately 1.2 W for both sites combined. Each 429-second session delivers approximately 21.5 J/cm² per site, approximately 0.26 kJ per site, and approximately 0.51 kJ for both sites combined. Over 18 sessions (3 times weekly for 6 weeks), cumulative exposure is approximately 386 J/cm² per site, approximately 4.6 kJ per site, and approximately 9.3 kJ for both sites combined.

808-nm near-infrared laser light is delivered through a headset forming approximately uniform, round beams of approximately 12 cm² at each of 2 bilateral frontal scalp sites (EEG positions AF3/F3 and AF4/F4; approximately 24 cm² total), irradiated simultaneously. Arms: (1) CW, Medium Dose, approximately 300 mW/cm² average irradiance (3.6 W per site; 7.2 W both sites); (2) CW_LOW, approximately 50 mW/cm² (0.6 W per site; 1.2 W both sites); (3) PW, 42 Hz, 33% duty cycle, peak approximately 900 mW/cm² (10.8 W per site; 21.6 W both sites), average approximately 300 mW/cm² (3.6 W per site; 7.2 W both sites); (4) Sham, identical device and procedural cues, no therapeutic emission (0 mW/cm²). Sessions lasted 429 seconds, 3 times weekly for 6 weeks (18 sessions). Sham duration and procedures matched the active arms to maintain blinding.

다른 이름들:
  • 근적외선-TLT
실험적: Arm C - Experimental: Pulsed Wave (PW)

Participants receive bilateral 808-nm tPBM in pulsed mode over AF3/F3 and AF4/F4, using the same two round beams of approximately 12 cm² each (approximately 24 cm² total) and the same 429-second session duration as the other active arms. Light is pulsed at 42 Hz with a 33% duty cycle (pulse period approximately ~24 ms; approximately ~8 ms ON and approximately 16 ms OFF; approximately 18,000 pulses per session). Peak irradiance is approximately 900 mW/cm², corresponding to approximately 10.8 W peak optical power per site and approximately 21.6 W peak for both sites combined. Time-averaged irradiance is approximately 300 mW/cm², corresponding to approximately 3.6 W average per site and approximately 7.2 W average for both sites combined, matched to Arm A. Delivered energy is therefore identical to Arm A. This arm isolates waveform (pulsed vs continuous) at matched average irradiance and matched total delivered energy.

808-nm near-infrared laser light is delivered through a headset forming approximately uniform, round beams of approximately 12 cm² at each of 2 bilateral frontal scalp sites (EEG positions AF3/F3 and AF4/F4; approximately 24 cm² total), irradiated simultaneously. Arms: (1) CW, Medium Dose, approximately 300 mW/cm² average irradiance (3.6 W per site; 7.2 W both sites); (2) CW_LOW, approximately 50 mW/cm² (0.6 W per site; 1.2 W both sites); (3) PW, 42 Hz, 33% duty cycle, peak approximately 900 mW/cm² (10.8 W per site; 21.6 W both sites), average approximately 300 mW/cm² (3.6 W per site; 7.2 W both sites); (4) Sham, identical device and procedural cues, no therapeutic emission (0 mW/cm²). Sessions lasted 429 seconds, 3 times weekly for 6 weeks (18 sessions). Sham duration and procedures matched the active arms to maintain blinding.

다른 이름들:
  • 근적외선-TLT
가짜 비교기: Arm D - Sham Comparator: Sham tPBM

Participants undergo identical procedures with an identical-appearing device positioned over AF3/F3 and AF4/F4 that emits no therapeutic near-infrared light (0 mW/cm², 0 W, and 0 J at each site and for both sites combined). Session duration (429 seconds), frequency (3 times weekly for 6 weeks, 18 sessions), device setup, operator contact, and all visible and audible device cues are matched to the active arms to maintain blinding. Because 808-nm light is invisible, no perceptual cue distinguishes active from sham emission.

808-nm near-infrared laser light is delivered through a headset forming approximately uniform, round beams of approximately 12 cm² at each of 2 bilateral frontal scalp sites (EEG positions AF3/F3 and AF4/F4; approximately 24 cm² total), irradiated simultaneously. Arms: (1) CW, Medium Dose, approximately 300 mW/cm² average irradiance (3.6 W per site; 7.2 W both sites); (2) CW_LOW, approximately 50 mW/cm² (0.6 W per site; 1.2 W both sites); (3) PW, 42 Hz, 33% duty cycle, peak approximately 900 mW/cm² (10.8 W per site; 21.6 W both sites), average approximately 300 mW/cm² (3.6 W per site; 7.2 W both sites); (4) Sham, identical device and procedural cues, no therapeutic emission (0 mW/cm²). Sessions lasted 429 seconds, 3 times weekly for 6 weeks (18 sessions). Sham duration and procedures matched the active arms to maintain blinding.

다른 이름들:
  • 근적외선-TLT

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Effect on depressive symptoms
기간: Baseline, mid-treatment (Week 3), post-treatment (Week 6), and at 2-week follow-up (Week 8).

The primary outcome is change in depressive symptom severity in patients with Major Depressive Disorder (MDD), comparing three active doses of near-infrared transcranial light therapy (NIR-TLT) and Sham. Symptoms are measured using the 17-item Hamilton Depression Rating Scale (HAMD-17).

Baseline, mid-treatment (Week 3), post-treatment (Week 6), and at 2-week follow-up (Week 8).

2차 결과 측정

결과 측정
측정값 설명
기간
Secondary Outcome Measures
기간: QIDS-C and SDQ: baseline, mid-treatment (Week 3), and post-intervention (Week 6), EEG: baseline, mid-treatment (Week 3), and post-intervention (Week 6), FDG-PET: baseline and post-intervention (Week 6).

Self-report symptom scales: Quick Inventory of Depressive Symptomatology (QIDS-C) and Symptoms of Depression Questionnaire (SDQ), measured at the same intervals.

Neurophysiological biomarkers:

Resting-state EEG. Spectral power (delta, theta, alpha, beta) and functional connectivity will be assessed.

Cerebral glucose metabolism via FDG-PET in a substudy of 20 participants. Primary Region of Interest (ROI): Frontal Lobe. Secondary ROI: dorsolateral prefrontal cortex (DLPFC). Exploratory ROIs include other cortical/limbic regions.

QIDS-C and SDQ: baseline, mid-treatment (Week 3), and post-intervention (Week 6), EEG: baseline, mid-treatment (Week 3), and post-intervention (Week 6), FDG-PET: baseline and post-intervention (Week 6).

기타 결과 측정

결과 측정
측정값 설명
기간
Other Pre-Specified Outcomes
기간: Minimally at baseline, mid-treatment (Week 3), and end of treatment (Week 6).

Composite clinical scores (e.g., Z-score averaging of HAMD-17 and QIDS)

Safety and tolerability metrics, including:

Adverse events (AEs) Serious adverse events (SAEs) Scalp/site tolerability (erythema, discomfort) Suicidality assessments using the Columbia-Suicide Severity Rating Scale (C-SSRS)

Minimally at baseline, mid-treatment (Week 3), and end of treatment (Week 6).

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 8월 24일

기본 완료 (실제)

2025년 8월 1일

연구 완료 (실제)

2025년 8월 1일

연구 등록 날짜

최초 제출

2025년 4월 11일

QC 기준을 충족하는 최초 제출

2025년 4월 11일

처음 게시됨 (실제)

2025년 4월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 20일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다